Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.

By D. J. Drucker, John B. Buse, K. Taylor, D. Kendall, M. Trautmann, Dongliang Zhuang, L. Porter. The Lancet, 2008

1,079 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Update on the treatment of type 2 diabetes mellitus. (2016, background): “Exenatide LAR: Administration of exenatide LAR was proved more effective than highest dose of exenatide twice-daily [193,194] , sitagliptin and pioglitazone [195] , and insulin glargine [196] in T2DM patients treated with oral hypoglycaemic agents.”
GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art (2020, background): “Prandial glycemic excursions Can be reduced with appropriately dosed basal insulin Reduced through deceleration of gastric emptying (short-acting GLP-1 RAs) and the influence on insulin and/or glucagon secretion [31] Short-acting GLP-1 RAs maintain their effect on gastric emptying with continued adm”
Incretin-based therapies for type 2 diabetes mellitus (2009, background): “By contrast, injection-site reactions and antiexenatide antibodies were more common in individuals treated with once-weekly exenatide, and the subset of participants in this group with the highest antibody titers exhibited a modest reduction in efficacy”
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). (2009, background): “9%).[22] Although liraglutide has been compared with glimepiride,[13] rosiglitazone,[14] and insulin glargine,[17] showing superiority in”